Breckenridge Pharmaceutical Inc., a prominent player in the U.S. generic medicines market, has recently forged a partnership with Maiva Pharma Pvt. Ltd. This collaboration focuses on the production and supply of sterile injectable products primarily aimed at hospitals and clinics across the United States. By aligning with Maiva, Breckenridge enhances its role as a dependable supplier in the hospital sector, ensuring that critical care injectables are readily available.
Strengthening Market Position
Brian Guy, the president and chief commercial officer of Breckenridge, emphasized the importance of this collaboration. He stated that maintaining consistent access to critical care injectables aligns with their mission to serve the U.S. hospital community. This partnership not only bolsters Breckenridge’s presence in the hospital market but also reflects its commitment to expanding patient access to high-quality, affordable medicines. The collaboration marks a significant step in Breckenridge’s evolution into three distinct business lines: specialty, hospital, and retail.
Commitment to Quality and Reliability
Breckenridge Pharmaceutical continuously invests in enhancing the pharmaceutical supply chain within hospitals. Collaborating with Maiva Pharma, a company recognized for its expertise in sterile injectable manufacturing, allows Breckenridge to increase its production capacity. This partnership aims to strengthen the availability of essential medications throughout the nation, ensuring healthcare providers can offer reliable and cost-effective treatment options to their patients.
Expanding the Oncology Portfolio
In early March 2026, Breckenridge took a proactive step in the oncology sector by launching Pomalidomide capsules, a generic version of Pomalyst by Celgene. Developed in collaboration with Natco Pharma Limited from India, this product significantly enhances Breckenridge’s oncology portfolio. The introduction of Pomalidomide capsules underscores the company’s dedication to supporting patients with complex medical conditions by delivering affordable and effective treatment options.
Therapeutic Indications and Availability
Pomalidomide capsules serve multiple therapeutic purposes. They are indicated for adult patients with multiple myeloma who have undergone at least two prior therapies, including lenalidomide and a proteasome inhibitor, and who have experienced disease progression. Additionally, the product is approved for treating AIDS-related Kaposi sarcoma in patients who have failed highly active antiretroviral therapy. Available in strengths of 1 mg, 2 mg, 3 mg, and 4 mg, Pomalidomide is primarily distributed through specialty pharmacies and clinics.
Maiva Pharma’s Manufacturing Excellence
Maiva Pharma stands out as a leading manufacturer of sterile injectables, supplying over 45 products to the U.S. market. With more than three decades of expertise in sterile manufacturing, Maiva has established a strong reputation for delivering reliable injectable solutions. The company’s two state-of-the-art manufacturing facilities located near Bengaluru, India, employ around 1,200 skilled professionals dedicated to maintaining high standards of quality and compliance.
Comprehensive Sterile Capabilities
Maiva’s extensive sterile manufacturing capabilities encompass a wide range of formulations, including liquid, lyophilized, and suspension injectables, packaged in vials and IV bags. The company is also expanding its offerings to include prefilled syringes and cartridge systems. This commitment to operational excellence positions Maiva as a trusted partner in the global healthcare landscape, enhancing the quality of care provided to patients.
Conclusion
The partnership between Breckenridge Pharma and Maiva Pharma marks a strategic move to bolster the supply of sterile injectables in the U.S. hospital market. By combining their strengths, both companies are well-positioned to enhance patient access to essential medications and improve healthcare outcomes. As they continue to innovate and expand their offerings, they reinforce their dedication to quality and reliability in the pharmaceutical industry.
- Breckenridge Pharma partners with Maiva Pharma to enhance sterile injectable supply.
- The collaboration supports hospitals with critical care injectables.
- Pomalidomide capsules expand Breckenridge’s oncology portfolio.
- Maiva Pharma brings three decades of sterile manufacturing expertise.
- The partnership aims to improve patient access to affordable medications.
Read more → www.pharmabiz.com